About 43,430 results

Isolated third nerve palsy: Lessons from the literature and 4 case studies
MDedge Family Medicine; Lim Yi Wen, MBBS, MSOphth, Lott Pooi Wah, MSOphth, FRCOphth et. al.

Mar 9th, 2023 - Of all the cranial nerve (CN) palsies that affect the eye, the third (oculomotor) nerve palsy (TNP) requires the most urgent evaluation. 1 Third nerve dysfunction may signal an underlying neurologic emergency, such as ruptured cerebral aneurysm or giant cell arteritis.

Mastocytosis: Rare, underdiagnosed, potentially fatal
Helen Leask, PhD

Jan 24th, 2023 - Systemic mastocytosis is widely underdiagnosed, and many more hematologic oncologists should be looking for it. This call to action was issued late in 2022 by Stanford (Calif.

Head Injuries Decrease Long-Term Survival Time

Jan 23rd, 2023 - Head injuries decreased long-term survival time in a dose-dependent manner, longitudinal data showed. All-cause mortality was twice as high for adults who had sustained a head injury earlier in life (HR 1.99, 95% CI 1.88-2.11) compared with those who had no head injury, reported Holly Elser, MD, PhD, of the University of Pennsylvania in Philadelphia, and co-authors. Both the frequency of head h...

Prevalence of colorectal neoplasia 10 or more years after a negative screening colonoscopy

Jan 17th, 2023 - About The Study: The results of this study suggest that advanced colorectal neoplasm prevalence at screening colonoscopies conducted 10 or more years after a negative screening colonoscopy is low. Extension of the currently recommended 10-year screening intervals may be warranted, especially for female and younger participants without gastrointestinal symptoms. Authors: Thomas Heisser, M.Sc., o...

Oral Propranolol Used as Adjunct Therapy in Cutaneous Angiosarcoma
Emily Nyers, MD, David M. Perry, MD, PhD et. al.

Jan 5th, 2023 - To the Editor: Angiosarcoma is a malignancy of the vascular endothelium that most commonly presents on the skin. 1 Patients diagnosed with cutaneous angiosarcoma, which is a rare and aggressive malignancy, have a 5-year survival rate of approximately 30%.

Rapidly Growing Nodule Within a Previously Radiated Area of the Scalp
Anthony Thompson, BS, Alexzandra Mattia, BS et. al.

Jan 3rd, 2023 - The Diagnosis: Pseudoangiomatous Squamous Cell Carcinoma Pseudoangiomatous squamous cell carcinoma (PSCC), a variant of acantholytic squamous cell carcinoma (SCC), is a rare epithelial neoplasm that can mimic angiosarcoma. 1 Clinically, PSCC presents as a white-gray ulcer or nodular pink tumor on sun-exposed areas, typically on the head and neck.

The New Obesity Breakthrough Drugs

Dec 14th, 2022 - This article was originally published December 10 on Medscape editor-in-chief Eric Topol's substack "Ground Truths." There are many holy grails in medicine, with failure after failure, like finding a way to prevent Alzheimer's disease or a non-invasive means for accurately measuring ambulatory blood pressure. But one of the biggest and most daunting has been finding drugs that can tackle obesit...

New Oral SERD Elacestrant -- for Which Breast Cancer Patients?

Dec 14th, 2022 - SAN ANTONIO — Updated results with the investigational oral selective estrogen receptor degrader (SERD) elacestrant give a hint of where it could find a place in the treatment paradigm for estrogen receptor positive (ER+) and HER2- advanced or metastatic breast cancer. Elacestrant is currently awaiting approval from the US Food and Drug Administration, with a decision expected in February. Data...

T-DXd: 'Remarkable' Survival Gains in Advanced Breast Cancer

Dec 14th, 2022 - SAN ANTONIO —Trastuzumab deruxtecan (T-DXd, Enhertu) has yielded significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival for patients with advanced HER2+ breast cancer when used as second-line and in later lines of therapy, new data confirm. However, the reports also highlighted the potential problem of interstitial lung disease (ILD) as an adv...

Change Makers: Princess Ghida on Fighting Cancer in the Arab World

Dec 14th, 2022 - Dr John Whyte speaks with Princess Ghida Talal about cancer treatment and research efforts in the Arab World and the importance of addressing taboos and providing cancer care to everyone who needs it. This transcript has been edited for clarity. John Whyte, MD: Welcome, everyone. I'm Dr John Whyte, the chief medical officer at WebMD, and you're watching Change Makers: The Future of Health. Canc...

Doctors Who Choose Private Practice; Patients With Cancer Sue for Psilocybin; and Mindfulness, Exercise Don't Improve Memory

Dec 14th, 2022 - Doctors Who Choose Private Practice Some doctors buck the trend of getting corporate jobs and have chosen to return to private practice for many reasons. Even so, the pendulum has recently swung toward employment: Fewer than half of all physicians now work in private practice, the American Medical Association reports. But some doctors have left jobs and opened their own businesses because they ...

Low Risk of ALCL With Postmastectomy Implant Reconstruction

Dec 14th, 2022 - While there has been growing awareness of the risk of developing anaplastic large-cell lymphoma (ALCL) following cosmetic breast implant surgery, to date, there has been no study specifically concerning the risk of this complication among women who undergo implant reconstruction after a mastectomy. A new study, which the authors believe provides the first population-based estimate of the risk o...

Key Research on TNBC: Top 5 Picks From SABCS

Dec 13th, 2022 - SAN ANTONIO — While major reports on hormone receptor (HR)–positive breast cancer took center stage at the San Antonio Breast Cancer Symposium (SABCS) 2022, research highlighting new findings in triple-negative breast cancer (TNBC) stood out as well. Medscape Medical News spoke with SABCS program director Virginia Kaklamani, MD, leader of the Breast Cancer Program at UT Health, San Antonio, and...

Melanoma Mortality Rates Fell in 2010s as New Therapies Took Hold

Dec 13th, 2022 - A new generation of treatments appears to have caused U.S. melanoma mortality rates to plunge between 2013 and 2017 for the first time in 4 decades, a new study finds, although the dip appeared to stabilize over the next 2 years. Dr Navkirat Kahlon "This data is very encouraging and represents the real-world effectiveness of these newer therapies, which include immunotherapies and targeted ther...

High Response Rates With T-DXd in Early HER2-Low Breast Cancer

Dec 13th, 2022 - SAN Antonio – How do you shoot at an invisible target? It seems counterintuitive, but trastuzumab deruxtecan (T-DXd) (Enhertu), which combines an antibody targeted to HER2 with a toxic payload, showed promising preliminary activity against localized hormone receptor–positive breast cancers with only low levels of HER2 expression (HR+/HER2-low). Dr Aditya Bardia n the investigator-initiated TRIO...

Steep Price for Surviving Childhood Lymphoma: Epigenetic Aging

Dec 13th, 2022 - NEW ORLEANS — Children with Hodgkin lymphoma can be cured with intensive chemotherapy, radiation, and other modalities, but a large majority of patients who survive into adulthood may pay a steep price years later in terms of accelerated aging and neurocognitive impairment. The findings come from a study of nearly 500 individuals in their late 30s, of whom 215 were adult survivors of pediatric ...

Cancer Patients Struggle to Access Psilocybin Before They Die

Dec 13th, 2022 - In March 2020, when the world was struck by the news of the COVID-19 pandemic, Erinn Baldeschwiler received her own gut punch. She was diagnosed with stage IV metastatic breast cancer and was given about 2 years to live. Then 48, the mother of two teenagers had just started a new chapter in her life. She'd gotten divorced, moved to a new home, and left a small business she had spent 18 years cu...

Oral SERD Camizestrant Prolongs PFS vs Fulvestrant in Breast Cancer

Dec 13th, 2022 - The investigational selective estrogen receptor degrader camizestrant was associated with significantly longer progression-free survival for women with advanced estrogen receptor–positive, HER2-negative (ER+/HER2–) breast cancers, compared with the first-generation SERD fulvestrant Faslodex, in the SERENA-2 trial, shows a study recently presented at the San Antonio Breast Cancer Symposium. Amon...

CTC-guided Therapy Beats Physician Choice in Metastatic Breast Cancer

Dec 13th, 2022 - SAN ANTONIO — When choosing between chemotherapy and endocrine therapy for patients with hormone receptor (HR)+/HER2- metastatic breast cancer, allowing the results from a blood test that measures circulating tumor cell (CTC) count to overrule physician's choice of therapy can significantly improve overall survival. But are these results enough to change clinical practice? One expert reacting t...

Chemotherapy Meets Its Match Against Aggressive ER+/HER2– Breast Cancers

Dec 13th, 2022 - SAN ANTONIO – Results of a study being hailed as practice changing showed that, for pre- or perimenopausal women with aggressive hormone receptor-positive, HER2-negative (HR+/HER2–) untreated breast cancers, the combination of the cyclin-dependent kinase 4/6 (CDK4/6) inhibitor ribociclib (Kisqali) and endocrine therapy offers a safer and equally efficacious alternative to combination chemothera...